Mobile

An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004122-24

An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Study CFTY720D2301E1 is designed to assess the following properties of FTY720 in patients with relapsing MS: • To evaluate long-term safety and tolerability • To evaluate long-term efficacy

Critère d'inclusion

  • Relapsing-Remitting Multiple Sclerosis

Liens